scholarly article | Q13442814 |
P2093 | author name string | Stephen J Thomas | |
P2860 | cites work | Norwalk virus shedding after experimental human infection | Q22305638 |
Dengue and US Military Operations from Spanish–American War through Today | Q24736754 | ||
Microevolution of Dengue Viruses Circulating among Primary School Children in Kamphaeng Phet, Thailand | Q27486119 | ||
Dengue: a continuing global threat | Q28298464 | ||
Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards | Q28476176 | ||
Microevolution and virulence of dengue viruses | Q28742358 | ||
Challenge studies of human volunteers: ethical issues | Q29051434 | ||
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial | Q29616259 | ||
Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century | Q29616264 | ||
Research on dengue during World War II | Q29619423 | ||
Potential role of human challenge studies for investigation of influenza transmission | Q30405341 | ||
Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience | Q33443281 | ||
Determinants of Inapparent and Symptomatic Dengue Infection in a Prospective Study of Primary School Children in Kamphaeng Phet, Thailand | Q33841925 | ||
Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand | Q33959784 | ||
Report of an NIAID workshop on dengue animal models | Q34058747 | ||
Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation | Q34840845 | ||
Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques | Q35031833 | ||
Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants | Q35131443 | ||
Economic cost of dengue in Puerto Rico | Q35910510 | ||
Animal Models of Dengue Virus Infection | Q37987131 | ||
Dengue and chikungunya in travelers: recent updates | Q38028785 | ||
Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study | Q38874657 | ||
Dengue: A reemerging concern for travelers | Q39090523 | ||
Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines | Q40265040 | ||
A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness | Q40329672 | ||
"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation | Q40415284 | ||
Sonographic findings of healthy volunteers infected with dengue virus | Q40420430 | ||
Dengue fever in US military personnel in Haiti | Q40650597 | ||
An Analysis of Fevers of Unknown Origin in American Soldiers in Vietnam | Q40953912 | ||
Experimental studies on dengue. I. Isolation, identification and modification of the virus | Q41051723 | ||
PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE. | Q41092633 | ||
Further Experiments in the Etiology of Dengue Fever | Q41100623 | ||
Dengue Surveillance among French Military in Africa | Q42571344 | ||
The economic burden of dengue | Q43151069 | ||
Experimental human challenge infections can accelerate clinical malaria vaccine development | Q44156054 | ||
P433 | issue | 7 | |
P921 | main subject | immunology | Q101929 |
Dengue virus | Q476209 | ||
P304 | page(s) | 1587-1590 | |
P577 | publication date | 2013-03-06 | |
P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
P1476 | title | Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development | |
P478 | volume | 9 |
Q34479588 | Assessing the epidemiological effect of wolbachia for dengue control |
Q92093930 | Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions |
Q30361791 | Consultation on dengue vaccines: progress in understanding protection, 26-28 June 2013, Rockville, Maryland. |
Q33676842 | DHIM supporting immunologic investigations and the identification of immune correlates of protection |
Q38242596 | Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects |
Q28542607 | Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions |
Q30279261 | Design, recruitment, and microbiological considerations in human challenge studies. |
Q38609515 | Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward |
Q33924674 | Immune correlates for dengue vaccine development |
Q90462841 | Insights from direct studies on human dengue infections |
Q38870485 | Investigational drugs in early development for treating dengue infection. |
Q38368332 | Prevention and Control Strategies to Counter Dengue Virus Infection |
Q42379418 | Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference |
Q34640272 | Review article: Research on dengue during World War II revisited |
Q59360735 | The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy |
Q33676847 | The role of the mosquito in a dengue human infection model |
Q27014663 | Vaccine-mediated immunity against dengue and the potential for long-term protection against disease |
Search more.